AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05709600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fasting mimicking diet
Description: Intermittent fasting with human fasting mimicking diet (Prolon®) will be performed for five days prior to living kidney donation in the donor. Prolon® a plant-based diet designed to attain fasting-like effects while provide providing both macro- and micronutrient. Each participant will obtain Prolon® diet during the first visit and the diet will stored at the participant's home at room temperature. Additionally, the participant will receive a food plan for the exact consumption of the diet. Regular phone with a predefined standardized questionnaire will be used to determine each participant's well-being, as well as his or her dietary adherence. Furthermore, the participants will be asked to write down each consumed food items they are consuming in diet-book, which is handed to them during the first visit.~The participants are only allowed to consume water, coffee or tea without sugar simultaneously to the Prolon® diet.
Study NCT05709600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic diet
Description: Isocaloric, ketogenic diet will be performed for seven days prior to living kidney donation in the donor.~The ketogenic diet is based on the KetoCal 4:1 formula diet (Nutricia Milupa GmbH, Erlangen, Germany). Main fat sources are plant oils including palm oil and sunflower oils. The formula diet is provided as a powder that has to be mixed with water before use. To avoid a shortage in protein uptake supplement formula diets K-AM and Fortimel® (both Nutricia Milupa GmbH, Erlangen, Germany) will be used additionally. Salt uptake will be standardized employing either broths or salt tablets to not interfere with the steady-state salt and water homeostasis. A salt ingestion of 5g/day, which is common for western diets, is aimed at. The participants will receive a daily food plan by the dietetics at the University Hospital of Cologne to ensure standardized food consumption
Study NCT05709600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary restriction of sulfur containing amino acids
Description: Isocaloric, dietary restriction of sulfur containing amino acids will be performed for seven days prior to living kidney donation in the donor.~A dietary restriction of sulfur containing amino acids without restriction in protein uptake will be achieved by following the X Met X Cys Maxamaid formula diet (Nutricia Milupa GmbH, Erlangen, Germany). The formula diet is provided as a powder that has to be mixed with water before use. A minimum of methionine and cysteine uptake (10% of the common uptake per day) will be achieved by consuming individuial calculated amounts of the Fortimel® formula diet (Nutricia Milupa GmbH, Erlangen, Germany). To avoid a restriction in fat and energy uptake additionally the Calogen and Duocal formula diets (both Nutricia Milupa GmbH, Erlangen, Germany) will be used. A salt ingestion of 5g/day, which is common for western diets, is aimed at. The participants will receive a daily food plan to ensure standardized food consumption.
Study NCT05709600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Group ( healthy, low-fat, moderate protein and high carbohydrate diet)
Description: Participants in the control group will be instructed to adhere to a healthy, low-fat, moderate protein and high carbohydrate diet as described in current nutritional recommendations. The control diet will be based on the formula diet Fortimel® (Nutricia Milupa GmbH, Erlangen, Germany). Salt uptake will be standardized employing either broths or salt tablets to not interfere with the steady-state salt and water homeostasis. A salt ingestion of 5g/day, which is common for western diets, is aimed at.
Study NCT06498011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Graded Repetitive Arm Supplementary Program (GRASP)
Description: The home-based exercise programme will be based on the Home Graded Repetitive Arm Supplementary Program focusing on stretching, arm strengthening, hand strengthening, coordination and hand skills. The Home Graded Repetitive Arm Supplementary Program will be delivered 2 hours/session, 3 times/week, for 6 weeks.
Study NCT06498011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated Somatosensory-MOtor training using a COgnitive approach(iCOSMO)
Description: The first training approach of iCOSMO will focus on integrated somatosensory-motor variables during reaching and object manipulation (60 minutes). The second training approach will focus on proprioceptive, motor and cognitive tasks using the Kinarm robotic exoskeleton (60 minutes). iCOSMO will be delivered 3 times per week (2 hours per session) for 6 weeks (Total: 36 hours of treatment).
Study NCT05638698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG01 Vaccine
Description: used to assess molecular disease control rate when combined with other interventional methods.
Study NCT05638698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QS-21
Description: used to assess molecular disease control rate when combined with other interventional methods.
Study NCT05638698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: used to assess molecular disease control rate when combined with other interventional methods.
Study NCT05153720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Ultrasound guided erector spinae plane block
Study NCT05153720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: Ultrasound guided caudal block
Study NCT05118828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavioural therapy
Description: AS-iCBT offers guided CBT intervention for anxiety and depression, each consisting of 6 modules. It is recommended for clients to complete 1 module weekly. The structure and content of the programme modules follow evidence-based CBT principles, and comprises cognitive and behavioural components such as self-monitoring, gradual stimulus control, exposure, behavioural activation, and cognitive restructuring. It is recommended that therapist support is provided weekly during short sessions that focus on progress monitoring and feedback on completed work. Support sessions should last 15-20 minutes and are preferably delivered by phone or video conference.
Study NCT05118828 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual in Prompt Mental Health Care (TAU-PMHC)
Description: TAU-PMHC includes both low-intensity (guided self-help, group-based psychoeducation) and high-intensity CBT (F2F-CBT). The TAU-PMHC condition basically represents how PMHC services currently operates (i.e. a pragmatic stepped care model) and provides therapists with more flexibility to accommodate client needs and preferences.
Study NCT06374108 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive resistance training
Description: The RT exercise regime will focus on lower extremity exercises (60-90% of 1 repetition maximum) as well as incorporating functional exercises.
Study NCT06350682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthMPowerment (HMP)
Description: Participants will be provided access to the status neutral platform (HMP)mobile app for 12 months exposure period or a delayed access period. The HMP is developed specific to RISE and will be adapted based off feedback from each local site via stakeholders/YABs. The HMP will encompass a range of features including a robust content management system and back end administrative dashboard, multi media resources and information center, social support features such as connections to peers and providers, interactive activities and self assessments, and flexible medication and health trackers. In addition the app will support HIV/STI test kit ordering and results portal and a gamified reward system. With real time analytics to monitor user engagement and response with the DHI we can adapt the delivery of tailored content to fit emergent HIV prevention and care challenges.
Study NCT04914429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab 100 mg will be administered as a SC injection.
Study NCT04914429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guselkumab
Description: Guselkumab 100 mg will be administered as a SC injection.
Study NCT04914429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as a SC injection.
Study NCT04914429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as a SC injection.
Study NCT06084923 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Patients will be observed after ibrutinib discontinuation and data on ibrutinib discontinuation, reatreatment and outcome will be collected
Study NCT05537116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback
Description: Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
Study NCT05537116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback and text messages
Description: Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
Study NCT05537116 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Only
Description: Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
Study NCT06643039 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant.
Study NCT06643039 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode.
Study NCT04635475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE Bundle
Description: Toolkit to build capacity where students receive education and provide symptom based and tailored accommodations after concussion
Study NCT06487845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: IR tablets, oral
Study NCT06487845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to BAY3283142
Study NCT05677997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Sessions to go through goals, problem areas, areas they want to improve.
Study NCT06513065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin c
Description: Mitomycin is a tumour antibiotic isolated from the broth of Streptomyces species. It has alkylating properties, which results in DNA cross-linking. Once MMC enters the tumour cell, it needs microsomal modification by various enzymes to be transformed into active state; free radicals constituted of semiquinones of MMC are responsible for its cytotoxic effects.~Mitomycin is licenced in the UK and recommended by NICE for intraperitoneal chemotherapy.
Study NCT06513065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin c
Description: Mitomycin is a tumour antibiotic isolated from the broth of Streptomyces species. It has alkylating properties, which results in DNA cross-linking. Once MMC enters the tumour cell, it needs microsomal modification by various enzymes to be transformed into active state; free radicals constituted of semiquinones of MMC are responsible for its cytotoxic effects.~Mitomycin is licenced in the UK and recommended by NICE for intraperitoneal chemotherapy.
Study NCT06608147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling
Description: sternal bone marrow aspiration
Study NCT04950400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrelizumab + chemotherapy + apatinib
Description: Subjects will receive 200 mg of karizumab every three weeks，Pemetrexed 500 mg / m2 was given on the first day of each cycle,Every three weeks was a period of administration,Carboplatin AUC 5 was given on the first day of each cycle and every three weeks was a cycle，Paclitaxel 175 mg / m2 was given on the first day of each cycle, and every three weeks was an administration cycle，with intravenous drip，Apatinib, 250 mg, oral, once a day (PO, QD), every 3 weeks as a cycle.
Study NCT06358729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Typical Nipple
Description: Infants are fed their typical milk/formula by their caregiver when hungry, one feeding with their typical nipple.
Study NCT06358729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenging Nipple
Description: Infants are fed with a smaller sized nipple (i.e. with a smaller aperture, slowing the rate of milk delivery).
Study NCT05157269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Two NTZ 300 mg extended release tablets administered orally with food twice daily for 5 days
Study NCT05157269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two matching placebo tablets administered orally twice daily for 5 days
Study NCT05157269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin Super-B Complex
Description: Vitamin Super-B Complex administered orally with food twice daily for 5 days to maintain the blind
Study NCT05157269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Super-B Complex
Description: Vitamin Super-B Complex administered orally with food twice daily for 5 days to maintain the blind
Study NCT06674915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 capsules
Description: Oral 50 mg.
Study NCT06622655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered orthosis
Description: Home rehabilitation (2 months, 30 minutes/day, 5 days/week) during which subjects will practice walking with the device at home.
Study NCT06728709 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound detection of any abnormal ultrasonographical findings.
Description: ultrasound assessment within 24 hours. Then reassessment every 48 hours or when the patient develops respiratory distress.~While the patient is in a supine or semi-recumbent position, and the probe is in a short axis. The 12-region technique will be used. The areas are six on each side of the chest. each region will be scored using the LUS aeration score. as follows: 0, A-pattern with 0-2 B-lines; 1, more than 2 separated B-lines; 2, multiple coalescent B-lines; or 3, lung consolidation, . A global LUS score will be calculated at each time point and range from 0 to 36.~If posterior regions couldn't be done. The examiner will assess 8 regions -Anterior chest wall ( ACW), Anterior axillary line (AAXL), costo-phrenic angle (COSTO), Postero-lateral alveolar \&/ or pleural syndrome (PLAPS) right and left -will be scored.~The venous status will be assessed through a subcostal view for inferior vena cava diameter.
Study NCT06729320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood mononuclear cells
Description: Intravenous infusion of UCB-MNCs (3×10\^8/ time, once a week, four times in total)
Study NCT06729320 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hematopoietic recovery therapy
Description: Including but not limited to G-CSF, TPO, TPO receptor agonists, transfusions of red blood cells, platelets, etc.
Study NCT06729320 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional hematopoietic recovery therapy
Description: Including but not limited to G-CSF, TPO, TPO receptor agonists, transfusions of red blood cells, platelets, etc.
Study NCT06728826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior Pericardiotomy
Description: The surgeon will perform a posterior pericardiotomy while the patient is on cardiopulmonary bypass. In detail, the surgeon will use cautery to make a 4- to 5-cm opening in pericardium between the left inferior pulmonary vein and the diaphragm. Then a soft channel drain will be placed through the posterior pericardium, the pericardiotomy and into the left pleural space.
Study NCT06728501 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes education
Description: Patients receive 5 hours of diabetes education
Study NCT06729255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiZact-assisted epidural placement
Description: The standard epidural kit used with the EpiZact device to place a midline epidural using the landmark technique between the L2 and L5 vertebral bodies. The patient's back will be sterilized with a 2% chlorhexidine/70% isopropyl alcohol applicator. The epidural will be placed with a 17-gauge 3.5-inch Tuohy needle. Once the Tuohy needle is appreciated to be engaged in ligament the EpiZact device will be filled with sterile and attached to the Tuohy via a Luer connector. The green button on the EpiZact device will then be pressed to prime the device. The EpiZact device and Tuohy needle will be advanced as a unit in continuous fashion or with intermittent advancement. Upon sensing a loss of resistance, the EpiZact device will provide a visual and tactile signal, halting needle advancement and signaling that the epidural catheter should be threaded through the Tuohy needle.
Study NCT06728618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Tislelizumab, Cetuximab, Cisplatin and Nab-paclitaxel
Description: Neoadjuvant treatment: the participants will receive Tislelizumab 200 mg, Cisplatin 75 mg/m2, Nab-paclitaxel 260 mg/m2 (each 3-week cycle) and Cetuximab (400 mg/m2 first time and followed 250 mg/m2, day 1, day 8, day 15) for 2 cycles.~Adjuvant treatment: the participants will receive Tislelizumab 200 mg (each 3-week cycle, a total of 8 cycle) and Cetuximab (250 mg/m2, each 2-week, a total of 12 cycle) for a total of half a year.
Study NCT06727929 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of gingival crevicular fluid, ELISA
Description: GCF samples were collected at baseline and at the 6-8 -week follow-up appointment after non-surgical periodontal treatment . After removing the supragingival plaque from the interproximal surfaces with sterile curettes, these sample surfaces were isolated with cotton rolls and slightly air-dried to avoid contamination. Standardized paper strips were inserted 1 to 2 mm into the gingival sulcus and held for 30 seconds to collect GCF. Strips contaminated with blood or saliva were discarded and not evaluated. The paper strips were transferred to a precalibrated Periotron 8000 device to measure the fluid volume. Paper strips were placed in sterile Eppendorf tubes and stored at -80C, until laboratory analysis. The level of GCF Dkk-1 and sFRP5 levels was measured by ELISA using commercial kits.
Study NCT06728436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CuidaTEXT
Description: CuidaTEXT is a multidomain, bilingual 6-month text message intervention that includes delivery and content features tailored to Latino caregivers. All caregivers receive one core daily automatic message on five domains: ADRD education, social support, self-care, ADRD care management, and behavioral symptoms. Caregivers can access on-demand automatic messages to expand on the five domains via sending keywords and interact with a coach via a live chat for more personalized help.
Study NCT06729749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioptron Pro 1 Class II
Description: Bioptron Pro 1 Class II: Made by Bioptron AG, Wollerau, Switzerland, a device with a floor stand emits a polarized light lamp. The device has an ergonomic table stand that can be combined with a functional floor stand, allowing flexible use in domestic and professional environments. easily adjustable height and head inclination and the ability to rotate the device head up to 360 allow a convenient usage of nearly any position. Treatments can easily be timed by a control panel down to 30 seconds, an integrated distance rod ensures the recommended distance from the skin surface It will be used for the treatment procedures for all participants in group B only with the following parameters, Wavelengths ranging from 480-3400 nm, Degree of polarization >95% (590 - 1550 nm), Specific power density Av. 40 mW/cm2 Light energy per minute av.2.4 J/cm2, Light Intensity per min. 10.000 lux, Weight without stand 3.4 kg and Weight with stand7.8 kg ,Energy consumption in sleep mode0.5
Study NCT06729749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: All participants in both groups will take this supplements daily for 3 months
Study NCT06729749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: All participants in both groups will take this supplements daily for 3 months
Study NCT06729437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS + Therapeutic eccentric exercise
Description: A direct current of 1.5 mA will be applied for 20 minutes to the primary motor cortex (M1) during each session of eccentric exercises.